SCHEMBL18558245

SCHEMBL18558245

CC(C)CN/C(=N/C(=O)c1cccc(C#N)c1)Nc1cc(-c2ccc(F)cc2)n[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 2/20 0.39
GPR139 Q6DWJ6 1/20 0.38
MAPK1 P28482 2/20 0.37
MCHR1 Q99705 1/20 0.37
HDAC2 Q92769 6/20 0.36
HDAC3 O15379 5/20 0.36
HDAC4 P56524 5/20 0.36
HDAC1 Q13547 5/20 0.36
HDAC7 Q8WUI4 5/20 0.36
HDAC10 Q969S8 5/20 0.36
HDAC11 Q96DB2 5/20 0.36
HDAC8 Q9BY41 5/20 0.36
HDAC6 Q9UBN7 5/20 0.36
HDAC9 Q9UKV0 5/20 0.36
HDAC5 Q9UQL6 5/20 0.36
NCOR2 Q9Y618 4/20 0.36
PPARG P37231 1/20 0.36
SCN9A Q15858 2/20 0.35
PRKAA2 P54646 1/20 0.34
CDC7 O00311 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18558338 0.93 GPR139 (0.38) VNN1GPR139MAPK1MCHR1CDC7
SCHEMBL18558204 0.92 VNN1 (0.40) VNN1GPR139MCHR1CDC7DAPK3
SCHEMBL18558434 0.89 HDAC3 (0.39) GPR139HDAC2HDAC3HDAC4HDAC1
SCHEMBL18558028 0.89 VNN1 (0.39) VNN1GPR139MAPK1HDAC2PPARG
SCHEMBL18558565 0.88 VNN1 (0.39) VNN1MAPK1MCHR1HDAC2HDAC3
SCHEMBL18558035 0.87 MAPT (0.46) VNN1
SCHEMBL18558579 0.86 HDAC3 (0.44) HDAC2HDAC3HDAC4HDAC1HDAC7
SCHEMBL19362653 0.86 VNN1 (0.38) VNN1GPR139MAPK1HDAC2PPARG
SCHEMBL9905160 0.85 HDAC3 (0.36) HDAC2HDAC3HDAC4HDAC1HDAC7
SCHEMBL9905165 0.85 HDAC3 (0.36) HDAC2HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932313-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-04-03 US disclosed
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-09-21 US disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME VNN1 2342/4885GPR139 4205/4885MAPK1 2483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.